Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. Obexelimab is a non-depleting anti-human CD19 mAb with an Fc region engineered to have high affinity for human FcγRIIb, thereby co-engaging BCR and FcγRIIb. To assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Seung Y., Pong, Erik, Bonzon, Christine, Yu, Ning, Jacob, Chaim O., Chalmers, Samantha A., Putterman, Chaim, Szymkowski, David E., Stohl, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773957/
https://www.ncbi.nlm.nih.gov/pubmed/33409482
http://dx.doi.org/10.1016/j.jtauto.2020.100075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773957/
https://www.ncbi.nlm.nih.gov/pubmed/33409482
http://dx.doi.org/10.1016/j.jtauto.2020.100075

Ejemplares similares